Australian biotech market watch 28/09/09
Monday, 28 September, 2009
The ASX200 opened sharply lower as expected, and was sitting at 4659 at 11:00am.
Among the pharmaceutical stocks, market heavyweight CSL Limited (ASX:CSL) was down 52c to $33.85
Photoprotective drug manufacturer, Clinuvel Pharmaceuticals (ASX:CUV) slumped nearly 6% to 31.5c after releasing its full year financial results – a 32% drop in revenues and a loss of $15.3M
Cellistis Limited (ASX:CST) fared little better, dropping 12c to $3.25 despite its recent announcement of a record $8.2M annual profit. The Cellistis share price had recently spiked as high as $4.00 and had more than tripled since February.
More positive numbers for Acrux (ASX:ACR) up almost 5% to $1.58 and Chemgenex (ASX:CXS) up almost 4% to 78.5c
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
